{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:23:10Z","timestamp":1781220190376,"version":"3.54.1"},"reference-count":54,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":735,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2010,1]]},"abstract":"<jats:p>Extended\u2010interval once\u2010daily dosing with the aminoglycoside tobramycin has been proven to be equally efficacious as traditional thrice\u2010daily dosing for treatment of the pulmonary exacerbations of cystic fibrosis in adults and children older than 5 years. The frequencies of acute ototoxicity and nephrotoxicity do not appear to be significantly different between patients treated with once\u2010versus thrice\u2010daily dosing, and the risk of acute nephrotoxicity may actually be lower in pediatric patients when once\u2010daily dosing is used. Long\u2010term studies are needed to fully assess the impact that cumulative treatments with once\u2010daily dosing have on renal and auditory function. An increase in antimicrobial resistance has been suggested with once\u2010daily dosing in the cystic fibrosis population. The extended\u2010interval aminoglycoside dose should be determined based on previous therapeutic drug monitoring. If the patient is aminoglycoside (tobramycin) na\u00efve, a dose of 10 mg\/kg once\/day is suggested, with the dose adjusted by using therapeutic drug monitoring to individualize therapy.<\/jats:p>","DOI":"10.1592\/phco.30.1.95","type":"journal-article","created":{"date-parts":[[2009,12,23]],"date-time":"2009-12-23T09:09:15Z","timestamp":1261559355000},"page":"95-108","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Extended\u2010Interval Once\u2010Daily Dosing of Aminoglycosides in Adult and Pediatric Patients with Cystic Fibrosis"],"prefix":"10.1002","volume":"30","author":[{"suffix":"Jr.","given":"William A.","family":"Prescott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerod L.","family":"Nagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.312.7027.338"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.114.1.e111"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.6.677"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.94.07091640"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/PL00008370"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128072-200204070-00005"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0954-6111(93)90010-W"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00221602"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/147.5.918"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02282885"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.1060"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.78.6.536"},{"key":"e_1_2_1_14_2","unstructured":"RiethmuellerJ FrankeP SchroeterTW et al.Optimized intravenous antibiotic treatment with ceftazidime (thrice daily vs continuous) and tobramycin (thrice vs once daily) in CF patients. Presented at the 24th European cystic fibrosis conference Vienna Austria June 69 2001."},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17906-9"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl328"},{"key":"e_1_2_1_17_2","first-page":"CD002009","article-title":"Once\u2010daily versus multiple\u2010daily dosing with intravenous aminoglycosides for cystic fibrosis","author":"Smyth AR","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1995.tb04354.x"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-5994.2001.00010.x"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.10036"},{"key":"e_1_2_1_21_2","unstructured":"CheongJ JacklinA HodsonM.The influence of the TOPIC study on the prescribing guidelines of aminoglycosides in cystic fibrosis units. Presented at the North American cystic fibrosis conference Orlando FL October 2325 2008."},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200812-1845PP"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/158.4.831"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/27.suppl_C.29"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/158.1.7"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-199611040-00006"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2005.02.011"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.5.1115"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.809-813.2000"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/42.1.103"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm097"},{"key":"e_1_2_1_32_2","unstructured":"TjonJA ChanC MurphyL et al.Clinical evaluation of once\u2010daily dosing tobramycin guidelines in paediatric patients with cystic fibrosis. Presented at the North American cystic fibrosis conference Orlando FL October 2325 2008."},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1086\/313692"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.112.5.1208"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jac.a020865"},{"issue":"29","key":"e_1_2_1_36_2","first-page":"326","article-title":"Pharmacokinetics and safety of once\u2010daily tobramycin in children with cystic fibrosis [abstract]","volume":"41","author":"Hamner JR","year":"2006","journal-title":"Pediatr Pulmonol"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1754.2006.00944.x"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.03045.x"},{"key":"e_1_2_1_39_2","unstructured":"SlagterR AlffenaarJ DuivermanE UgesD RottierB.IV tobramycin in pediatric CF patients: once or twice daily. Presented at the North American cystic fibrosis conference Orlando FL October 2325 2008."},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.3.431"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.2.325"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2006.12.007"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/37.5.1040"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf168"},{"key":"e_1_2_1_45_2","first-page":"27","article-title":"Aminoglycoside nephrotoxicity","volume":"17","author":"Swan SK","year":"1997","journal-title":"Semin Nephrol"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.5.1003"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.6.797"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0709(97)90078-8"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39301.680266.AE"},{"key":"e_1_2_1_50_2","first-page":"263","article-title":"Twelve\u2010hour pharmacokinetics and ototoxicity of tobramycin in CF [abstract]","volume":"9","author":"Phillips J","year":"1993","journal-title":"Pediatr Pulmonol"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00995-05"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2006.05.015"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199902000-00010"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199302000-00010"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.3.650"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.30.1.95","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.30.1.95","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:33:45Z","timestamp":1761046425000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.30.1.95"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.1592\/phco.30.1.95"],"URL":"https:\/\/doi.org\/10.1592\/phco.30.1.95","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}